Upton R N, Zheng D A, Grant C, Martinez A M
Department of Anaesthesia and Intensive Care, Royal Adelaide Hospital, University of Adelaide, SA, Australia.
J Pharm Pharmacol. 2000 Feb;52(2):181-9. doi: 10.1211/0022357001773832.
A recirculatory physiological model of the determinants of the myocardial concentrations of lignocaine after intravenous administration was developed in sheep and validated with the intention of analysing and predicting the outcome of altered dose regimens and various pathophysiological states on the initial myocardial concentrations of lignocaine. The structure and parameters of the model were determined by hybrid modelling of the time-courses of the pulmonary artery, arterial and coronary sinus concentrations of lignocaine after the intravenous administration of 100 mg of lignocaine over 5 min to 5 chronically instrumented sheep. The model accounted for the determinants of the myocardial concentrations via compartments for venous mixing, the lung (a single-compartment model with a first-order loss) and the heart (a single flow-limited compartment). Recirculation and the remainder of the body were represented as a single tissue pool with a clearance term. The distribution volume of the heart was 0.42+/-0.009 L, which gave a half-time of myocardium:blood equilibration of 2.37 min. The distribution volume of the lungs was 5.40+/-0.23 L, with an apparent first-order loss of 1.02 L min(-1) representing deep distribution or metabolism. The validity of the model was tested by comparing the predictions of the model with the equivalent data collected in 6 sheep when lignocaine (89 mg) was administered via a complex dose regimen with a faster initial rate of infusion (39.1 mg min(-1)), declining exponentially to basal infusion rate (7.02 mg min(-1)) over 8 min. The predictions of the model were in general agreement with these data. It is concluded that the model was sufficient to account for the effect of altered dose regimens of lignocaine on the time-course of its myocardial concentrations.
在绵羊身上建立了一个静脉注射后利多卡因心肌浓度决定因素的再循环生理模型,并进行了验证,目的是分析和预测改变剂量方案和各种病理生理状态对利多卡因初始心肌浓度的影响。该模型的结构和参数通过对5只长期植入仪器的绵羊在5分钟内静脉注射100毫克利多卡因后肺动脉、动脉和冠状窦利多卡因浓度的时间进程进行混合建模来确定。该模型通过静脉混合、肺(具有一级消除的单室模型)和心脏(单血流限制室)的隔室来解释心肌浓度的决定因素。再循环和身体的其余部分被表示为一个具有清除项的单一组织池。心脏的分布容积为0.42±0.009升,心肌与血液平衡的半衰期为2.37分钟。肺的分布容积为5.40±0.23升,表观一级消除率为1.02升/分钟,代表深部分布或代谢。通过将模型预测与6只绵羊在以更快的初始输注速率(39.1毫克/分钟)通过复杂剂量方案给予利多卡因(89毫克),并在8分钟内指数下降至基础输注速率(7.02毫克/分钟)时收集的等效数据进行比较,来测试模型的有效性。模型预测与这些数据总体一致。得出的结论是,该模型足以解释利多卡因剂量方案改变对其心肌浓度时间进程的影响。